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ABSTRACT
Objective: Subclinical hypothyroidism (SCH) with thyroid-stimulating hormone (TSH) less than 10 µIU/ml is a common finding discovered during 
routine thyroid function testing. Thyroxine substitution and its benefits to alleviate dyslipidemia and oxidative stress (OXs) markers at this stage are 
a matter of debate.
Methods: This study aimed to investigate the influence of thyroxine substitution on lipid profile and OXs markers in newly diagnosed SCH subjects. 
The study included a total number of 50 newly diagnosed (20 treated and 30 untreated), SCH subjects aged 20-50 years with (TSH<10 µIU/ml), and 
free thyroxine (FT4) levels in the normal range. Patients on medications that could cause thyroid hormone dysfunction, diabetes mellitus, and current 
or pregnancy during the last 2 years were excluded from the study. Serum TSH, T3, T4, FT4, anti-thyroid peroxidase antibodies, total cholesterol (TC), 
high-density lipoprotein cholesterol (HDL), triglycerides (TG), low-density lipoprotein cholesterol (LDL), and ischemia modified albumin (IMA) were 
determined in all subjects at baseline and after 9 months.
Results: After thyroxine replacement, a significant decrease in TSH, LDL, IMA and an increase in FT4 were observed. The decrease in TC was not 
statistically evident. There was no significant change in T3, T4, TG, HDL, after treatment. The untreated group showed an insignificant increase only 
in TSH.
Conclusion: Thyroid substitution therapy has a favorable influence on lipid profile and OXs, where it particularly reduced LDL and IMA.
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INTRODUCTION
Subclinical hypothyroidism (SCH) is a common finding discovered 
during routine thyroid function testing with a prevalence reaching up 
to 10-20% worldwide [1-3]. SCH is a well-established clinical entity 
with biochemical evidence of cardiovascular risk similar to that of 
overt hypothyroidism in relation to atherogenic lipids and oxidative 
stress (OXs) markers when thyroid-stimulating hormone (TSH) levels 
are >10 µIU/ml [4-6].
Recent prevalence studies [1-3] show that 80-90% of patients with SCH 
have TSH <10 µIU/ml. Most of the studies taken up in the past decade 
did not categorize SCH subjects based on the degree of TSH elevation 
while concerning cardiovascular impact and management protocol in 
them. The data on this subdivision are scanty and evidence in favor 
of thyroxine therapy is not well established; hence, studies to assess 
the cardiovascular risk in the newly defined SCH patients are needed. 
Hence, this study aimed to study the influence of thyroxine substitution 
on lipids and OXs based on ischemia-modified albumin (IMA) in newly 
diagnosed SCH subjects with TSH<10 µIU/ml.
METHODS
A total of 50 newly diagnosed SCH subjects aged 20-50 years with 
TSH<10 µIU/ml and free thyroxine (FT4) levels in the normal range 
for a minimum period of 3 months (20 treated and 30 untreated) 
were followed prospectively for 9 months. Patients on medications 
that could cause thyroid hormone dysfunction, diabetes mellitus, 
and current or previous pregnancy in the last 2 years were excluded 
from the study. L-thyroxine (LT4) was administered at doses ranging 
from 25-100 µg/day.
Written informed consent was taken from all subjects. The study was 
approved by the Institutional Ethics Committee. Fasting serum TSH, T3, T4, 
FT4, anti-thyroid peroxidase (anti-TPO) antibodies, total cholesterol (TC), 
high-density lipoprotein cholesterol (HDL), triglycerides (TG), low-density 
lipoprotein cholesterol (LDL), IMA, and atherogenic index of plasma (AIP) 
were determined in all subjects at baseline and after 9 months.
Laboratory parameters
Thyroid function tests were performed by electrochemiluminescence 
assay. Anti-TPO antibody was measured using enzyme-linked 
immunosorbent assay (ELISA) kits with a normal range of 0.1-34.0 IU/L. 
TC, TG, HDL, LDL-C direct levels were estimated using Roche kits in fully 
automated biochemistry analyzer.
IMA estimation
IMA was estimated by colorimetry using the method developed by 
Bar-Or et al. [7]. The absorbance of the assay mixture was read at 
450 nm using ELISA reader. IMA was reported in absorbance units.
AIP was calculated using the formula (log [TG/HDL cholesterol]), 
and value over 0.5 has been proposed as the cutoff point indicating 
atherogenic risk [8]. The association between TG and HDL cholesterol 
reflected by this ratio depicts the balance between atherogenic and 
protective lipoproteins.
Statistical analysis
Comparisons between the patients at two-time points were performed 
using paired t-test for normally distributed data and Wilcoxon 
signed-rank test for nonparametric distribution. A p<0.05 was 
considered statistically significant.
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RESULTS
Thyroid function tests of both treated and untreated groups at 
induction and after 9 months of follow-up were compared (Table 1). 
Following thyroxine replacement, there was a significant decrease in 
TSH and increase in FT4 and T4, whereas no significant changes were 
observed in T3, anti-TPO values. Thyroid autoimmunity was evident in 
17 (85%) of subjects in the treated group. The untreated group showed 
an increase in TSH and in FT4 which was not statistically significant
Lipid and OXs markers were compared in both treated and untreated 
groups (Table 2). In the treated group, a significant decrease in LDL 
was observed. There was no significant change in TC, TG, HDL, and AIP 
after treatment. IMA an indicator of OXs was also reduced after LT4 
replacement. The untreated group had no significant alteration in any 
of the estimated parameters.
DISCUSSION
This study explores the effects of LT4 replacement therapy on OXs 
level and lipid profile in patients with SCH. LT4 substitution showed 
the favorable effect on lipid profile in SCH subjects of the present study. 
Earlier studies have shown inconsistent results. Few of the studies have 
reported no change in TC, TG, LDL, and HDL [9,10], whereas few showed 
a significant decrease in TC and LDL after LT4 replacement [11,12]. 
Majority of the studies [13] seem to have no significant effect on serum 
HDL and TG expects for few [14,15]. A significant decrease in LDL and 
a non-significant decrease in TC after the restoration of euthyroid state 
were observed in the present study.
In untreated SCH subjects, there was no significant variation in any of 
the biochemical parameters except for a further elevation in TSH. The 
percentage alteration in TSH and FT4 was 23% and 12%, respectively, 
after 9 months. Karmisholt et al. [16] reported that a 40% increase in 
TSH and 15% decrease in FT4 from the initial values can be considered 
significant in untreated stable SCH with TSH initially up to 12 mU/L in 
an 1-year follow-up.
IMA as measured using the ACB test is currently the most promising 
biomarker for early detection of ischemic stress [17]. Recent studies 
have reported a strong association of IMA with oxidative stress (OXs) 
and its generation depends on the extent of OXs [18]. Studies suggested 
that elevated IMA levels can be a clinically useful marker of oxidative 
damage to protein and OXs in hypothyroidism [19]. However, results 
of IMA in SCH are inconsistent and inconclusive [20-22]. In the 
present study, LT4 replacement in SCH patients caused a significant 
decrease in IMA levels. Our results contradictory to the finding of Erem 
et al. [23], wherein serum IMA levels did not decrease significantly after 
replacement. Ma et al. [19] reported a significant positive association 
between IMA levels and TPOAb in overt hypothyroid subjects and its 
reduction after LT4 replacement. Elevated anti-TPO in Hashimoto’s 
thyroiditis is found to be associated with OXs; similarly, hyperlipidemia 
of any cause is also reported to be associated with an increase in OXs 
and IMA levels [18,24,25]. In the present study, coexistence of elevated 
anti-TPO and high cholesterol levels (total and LDL) was found to be 
associated with high IMA levels at baseline which reduced on LT4 
replacement.
The mechanism of OXs in hypothyroidism seems to be multifactorial 
because thyroid hormone (T3) is associated with the regulation of 
prooxidant and antioxidant balance [26]. Direct effects of thyroid 
hormones on the regulation of antioxidant enzymes, protein, and 
vitamin are the proposed mechanisms associated with increased OXs 
[27,28]. The plausible explanations for altered OXs markers in SCH 
are attributed to the direct effects of TSH on OXs and inflammatory 
processes [29]. In contrast to this hypothesis, other studies supported 
the concept that OXs itself can alter circulating thyroid function 
parameters and can trigger the autoimmune process resulting in 
underactive thyroid condition [30,31].
The current study differs from most of earlier studies with respect to 
the TSH cutoff considered and recruitment of relatively young subjects 
without pre-existing alterations and other comorbidities at baseline. 
Smaller sample size and replacement therapy which are not placebo-
controlled are the major limitations of this study. Estimation of albumin 
adjusted-IMA would have provided further insights into the level of 
IMA. As our study group did not have any other complications except 
for slight alteration in TSH, this limitation is not likely to affect the 
conclusions drawn.
Dyslipidemia in SCH is often associated with altered LDL. OXs in 
SCH if not given due attention can cause oxidation of LDL resulting 
in oxidatively modified LDL, a potent proatherosclerotic mediator. 
The results of the current data demand conduction of large-scale 
prospective studies with more potent markers to elucidate the role of 
thyroid autoimmunity on lipids and OXs and to define the role of L-T4 
therapy on atherogenic lipids and OXs in SCH subjects with mildly 
elevated TSH.
CONCLUSION
Thyroxine substitution therapy had a favorable influence on lipid 
profile and OXs, where it significantly reduced both LDL and IMA.
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Table 1: Thyroid profile in levothyroxine‑treated and untreated 








Gender (M/F) (4/26) (1/19)
Age (years) 37±8 35±9
TSH (µIU/ml) 6.1±1.69 7.46±5.08 6.7±1.7 2.16±1.9*
FT4 (ng/dL) 1.09±0.26 0.962±0.13 0.97±0.73 1.71±0.43*
T3 (ng/mL) 1.06±0.13 1.03±0.16 1.01±0.15 1.12±0.28
T4 (µg/dL) 7.57±1.65 7.20±1.45 6.78±1.6 8.92±2.6*
Anti-TPO (IU/ml)# 12.46±7.3 13.7±10 283 (349) 234 (272)
Values are the mean±SD. Replacement effects of L-T4 were analyzed by paired 
t-test and by #Wilcoxon signed-rank test for nonparametric distribution. 
*p<0.05 after L-T4 replacement therapy. TSH: Thyroid-stimulating hormone, 
FT4: Free thyroxine, Anti-TPO: Anti-thyroid peroxidase antibodies
Table 2: Lipids and IMA in levothyroxine‑treated and untreated 








TC (mg/dL) 167±28 173±35 159±45 145±36
TG (mg/dL) 114±46 127±43 111±25 116±45
HDL (mg/dL) 44±8 44±10 41±7 40±6
LDL (mg/dL) 117±28 119±38 127±32 109±33*
AIP 0.36±0.19 0.44±0.20 0.39±0.11 0.47±0.18
IMA (ABSU) 0.70±0.18 0.75±0.32 0.80±0.33 0.53±0.16*
Values are the mean±SD. Replacement effects of L-T4 were analyzed by 
paired t-test. *p<0.05, TG: Triglycerides, HDL-c: High-density lipoprotein 
cholesterol, TC: Total cholesterol, LDL-c: Low-density lipoprotein cholesterol, 
AIP: Atherogenic index of plasma, IMA: Ischemia-modified albumin, 
ABSU: Absorbance units
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